secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2026-08-04T11:05:35+00:00
Accession:  0001420720-26-000014
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio appoints Molly Carr as CMO; grants 430,000 stock options at $1.40/share
----------------------------------------------------------------------------

- Dr. Carr appointed CMO effective July 31, 2026, leading global clinical strategy for obesity and cardiometabolic pipeline.
- She previously served as Clinical Head at Eli Lilly, overseeing insulin/glucagon portfolio including Phase 3 efsitora.
- Employment terms: $470,000 base salary, 40% target bonus, severance provisions.
- Inducement award: options to purchase 430,000 shares at $1.40, vesting 25% after one year then monthly over 3 years.
- Company advancing IBIO-600 and IBIO-610 into next clinical phases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000014/0001420720-26-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000014/ibio-20260722x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-26-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer